Kura Oncology (NASDAQ: KURA) reported a net loss of $68.3 million for the second quarter of 2026, resulting in an earnings per share (EPS) of $(0.77). This figure beat the analyst consensus estimate of $(0.87) by 11.49%, although it represents a slight widening from the $(0.75) loss per share recorded in the same period of 2025. The biopharmaceutical company posted total revenue of $20.9 million, which missed the analyst consensus estimate of $21.42 million by 2.55%. Despite the miss, this represents a 36.54% increase over sales of $15.288 million in the prior year period.

Commercial Launch Momentum

KOMZIFTI (ziftomenib) generated $9.1 million in net product revenue in 2Q 2026, a significant increase from zero in 2Q 2025. This represents a 57% quarter-over-quarter rise from the first quarter of 2026. The drug achieved approximately 115 new patient starts, up 35% from 1Q 2026, and secured more than 250 total prescriptions, including repeats, marking a 59% increase from the prior quarter.

In its second full quarter on the market, KOMZIFTI established a majority share of new patient starts in the relapsed or refractory NPM1-mutant acute myeloid leukemia (AML) menin inhibitor class. Management noted increasing physician preference and broader adoption across academic and community treatment centers.

Financial Performance

Collaboration revenue declined to $11.8 million from $15.3 million in 2Q 2025. Research and development (R&D) expenses remained relatively stable at $61.9 million, compared to $62.8 million in the prior year period. However, selling, general, and administrative (SG&A) expenses rose to $31.8 million from $25.2 million, reflecting costs associated with the commercial launch.

The net loss included $8.2 million in non-cash share-based compensation expense, up from $6.9 million in 2Q 2025. Other income, net, contributed $4.7 million, down from $6.5 million in the previous year.

What the Numbers Show

The divergence between rising SG&A expenses and flat R&D spending highlights the company’s transition from pure development to commercial execution. While R&D remained steady at roughly $62 million, SG&A increased by $6.6 million year-over-year, absorbing a larger portion of the limited revenue base. With collaboration revenue declining by approximately 23% year-over-year, the company’s reliance on internal product sales is growing, though these currently cover less than half of operating expenses. The beat on EPS despite the revenue miss suggests that cost controls in non-SG&A areas or favorable non-cash adjustments helped narrow the per-share loss relative to expectations.

Balance Sheet and Liquidity

As of June 30, 2026, Kura held $519.0 million in cash, cash equivalents, and short-term investments, down from $667.2 million at the end of December 2025. Working capital stood at $441.2 million, compared to $591.7 million at year-end. Long-term liabilities decreased slightly to $421.2 million from $447.3 million.

The company anticipates receiving $180 million in collaboration payments from Kyowa Kirin. Management stated that current resources are sufficient to fund the ziftomenib AML program through the top-line results of the pivotal Phase 3 KOMET-017 trial, expected in 2028.

Pipeline Updates

Clinical data presented at EHA 2026 showed durable activity for ziftomenib plus intensive chemotherapy in newly diagnosed AML patients. In parallel, darlifarnib demonstrated potential as a precision combination platform in solid tumors, with updated Phase 1 data showing response rates in KRAS-mutated cancers and renal cell carcinoma. Enrollment continues in multiple registrational studies, including KOMET-017 for frontline AML treatment.

Kura Oncology, Inc. (NASDAQ: KURA) announced on Aug. 10, 2026, that a manuscript detailing the discovery and preclinical characterization of ziftomenib has been published in Blood, the flagship journal of the American Society of Hematology. The publication underscores ziftomenib’s differentiated menin binding profile and its activity against specific resistance-associated mutations, reinforcing its potential as a foundational therapy across genetically defined acute leukemias. This scientific validation supports the company’s strategy to expand ziftomenib’s use beyond its current FDA-approved indication for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).

The findings describe the molecular properties that distinguish ziftomenib from other menin inhibitors, particularly its ability to retain activity against certain treatment-emergent MEN1 mutations associated with resistance. In the KOMET-001 clinical trial, the MEN1-M327I resistance mutation emerged in only 1 of 29 evaluable patients, indicating a low frequency of treatment-emergent resistance. Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology, stated that the publication captures the scientific journey from identifying the menin-KMT2A interaction as a therapeutic target to designing a potent inhibitor suitable for clinical development.

Preclinical Activity and Resistance Profile

The research, stemming from a collaboration between Kura Oncology and the University of Michigan initiated in 2014, evaluated ziftomenib across multiple leukemia models. The drug demonstrated potent inhibition of the menin-KMT2A interaction, suppressing key regulated genes such as MEIS1 and HOXA9, inducing differentiation, and reducing leukemia cell viability. These effects were observed in KMT2A-rearranged, NPM1-mutated, and NUP98-rearranged leukemia models.

Ziftomenib also induced leukemia regression and extended survival in multiple xenograft and patient-derived xenograft models. Notably, durable responses were observed after treatment discontinuation in a patient-derived model, suggesting lasting therapeutic benefit.

What the Numbers Show

The low emergence rate of resistance mutations is a critical differentiator for ziftomenib. With the MEN1-M327I mutation appearing in only approximately 3.4% (1 of 29) of evaluable patients in the KOMET-001 trial, ziftomenib demonstrates a favorable resistance profile compared to the broader class of menin inhibitors. This data supports the hypothesis that ziftomenib’s unique binding properties may delay or prevent the development of clinical resistance, potentially extending the duration of response for patients with relapsed or refractory AML.

Troy E. Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology, emphasized that the publication validates the properties enabling ziftomenib’s advancement from early discovery to an approved medicine. The company continues to pursue combination strategies with established standards of care to expand ziftomenib’s benefit to additional patient populations with menin-dependent acute leukemias, which represent up to 50% of eligible patients.

Safety Profile and Regulatory Status

Ziftomenib, marketed as KOMZIFTI in the U.S., carries a Boxed Warning for differentiation syndrome, which can be fatal. In clinical trials, differentiation syndrome occurred in 26% of patients with relapsed or refractory AML with an NPM1 mutation, including two fatal cases. Other serious adverse reactions included infection without an identified pathogen (29%) and febrile neutropenia (18%).

The drug can also cause QTc interval prolongation, reported in 12% of patients at the recommended dosage. Patients are advised to correct electrolyte abnormalities prior to treatment, and ECG monitoring is required. Concomitant use with strong CYP3A4 inducers or drugs that prolong the QTc interval should be avoided. Kura Oncology continues to advance ziftomenib in combination studies for newly diagnosed and relapsed AML, as well as in advanced gastrointestinal stromal tumors.